ArticleHLA2026
Non-HLA Autoantibodies Associate With a Positive Flow-Crossmatch Pre- and Chronic Lung Allograft Dysfunction Post- Lung Transplant.
Article in HLA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Antibodies to HLA are a major cause of chronic lung allograft dysfunction (CLAD) following lung transplantation (LTx), however mounting evidence indicates non-HLA autoantibodies may also play a role. LTx recipients may have increased autoantibodies related to their native disease, and these may impact both pre-transplant assays and LTx outcomes. The flow cytometry crossmatch (FXM) assay is often used peri-LTx to define immunological risk; however, the presence of autoantibodies in LTx recipients may associate with positivity in the FXM, and the clinical impact of this is unknown. In a retrospective, single-center cohort, we investigate the association of pre-transplant non-HLA autoantibodies on the FXM and subsequent CLAD. The serum of 68 LTx recipients was retrospectively tested for 39 autoantibody targets pre- and 12-months post-transplant. A further cohort of waitlisted LTx recipients (n = 25) with HLA antibody-negative FXM-positive sera was evaluated for the presence of these same 39 autoantibodies to determine the association of autoantibodies and FXM reactivity. CLAD status and freedom from CLAD were defined and analysed for all recipients. MFI strengths in five autoantibody targets associated with FXM positivity when compared to the HLA donor-specific and FXM negative patients. LTx recipients who were positive to ≥ 8 non-HLA autoantibodies had an increased risk of CLAD (HR = 3.09 p < 0.01) and a decreased freedom from CLAD (p < 0.01). Recipients with increased positivity to non-HLA autoantibodies pre-LTx demonstrate increased risk of CLAD and decreased freedom from CLAD. Furthermore, the strength of these autoantibodies is associated with FXM positivity in the absence of HLA antibodies. Further research with larger cohorts is required to better understand which autoantibody targets are responsible for CLAD outcomes, and to define best cut-offs to define reactivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.